← SynDRA
LETROZOLE
SynDRA canonical compound SYN0006820 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | CYP19A1 |
|---|
| Mechanism of action | Aromatase inhibitor |
|---|
| Indication | breast cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- CYP19A1 INHIBITOR
- Cytochrome P450 19A1 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- DRD2
- ABCC2
- KCNH2
- MMP9
- MMP1
- MC5R
- MC4R
- MC3R
- MAPK3
- MAPK14
- MAPK1
- MAOA
- LCK
- HTR6
- ESR1
- HTR2C
- HTR2B
- HTR2A
- HRH2
- HRH1
- HMGCR
- HDAC6
- FYN
- FLT1
- NPY1R
- NPY2R
- NR3C1
- OPRD1
- VDR
- USP1
- TSHR
- TBXAS1
- TACR2
- TACR1
- STS
- SLC6A4
- SLC6A3
- SLC6A2
- SIGMAR1
- SAMHD1
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Aromatase Inhibitors
- Aromatase Inhibitor
- Antineoplastic Agents
- Enzyme Inhibitors
- Estrogen Antagonists
- Hormone Antagonists
- Steroid Synthesis Inhibitors
ATC classes
- L02B · HORMONE ANTAGONISTS AND RELATED AGENTS
Cross-references
Synonyms
- FEMARA
- Femara
- KISQALI FEMARA CO-PACK (COPACKAGED)
- CGS 20267
- lerozole
- letrazole
- femara
- Letrozol
- CGS-20267
- NSC-759652
- Letrozole component of kisqali femara co-pack
- Femera
- Letoval
- Novartis Brand of Letrozole
- FEM-345
- Femara (TN)
- Letrozole [USAN:INN]
- CGS 20267, Femara, Piroxicam, Letrozole
- Letrozole (JAN/USP/INN)
- 1-[Bis-(4-cyanophenyl)methyl]-1,2,4-triazole
- 1-[bis(4-cyanophenyl)methyl]-1,2,4-triazole
- 4,4'-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile
- 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
- 4,4'-(1H-1,2,4-triazol-1-yl-methylene)-bis(benzonitrile)
- 4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile
- 4,4'-(1h-1,2,4-triazol-1-ylmethylene) bis-benzonitrile
- 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bis-benzonitrile
- 4,4'-(1h-1,2,4-triazol-1-ylmethylene)bisbenzonitrile
- LETRAZOLE
- Benzonitrile, 4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis-
- NSC 759652
- CHEMBL1444
- 7LKK855W8I
- CHEBI:6413
- NCGC00016973-01
- CAS-112809-51-5
- SMR000466343
Reported adverse events
- Alopecia
- Fatigue
- Headache
- Infection
- Nausea
- Asthenia
- Cataract
- Constipation
- Cough
- Depression
- Hypertension
- Insomnia
Look up LETROZOLE in the interactive SynDRA portal →